Matches in SemOpenAlex for { <https://semopenalex.org/work/W1926317532> ?p ?o ?g. }
- W1926317532 endingPage "63" @default.
- W1926317532 startingPage "56" @default.
- W1926317532 abstract "(R)-(+)-2-Amino-4-(4-fluorophenyl)-5-[1-[4-(4-fluorophenyl)-4-oxobutyl]+ ++pyrrolidin-3-yl]thiazole (NRA0045), a novel thiazole derivative, has high affinities for the human cloned dopamine D4.2, D4.4 and D4.7 receptors, with Ki values of 2.54, 0.55 and 0.54 nM, respectively. NRA0045 is approximately 91-fold more potent at the dopamine D4.2 receptor, compared with human cloned dopamine D2L receptor. NRA0045 also has high affinities for the serotonin (5-HT)2A receptor (Ki = 1.92 nM) and alpha-1 adrenoceptor (Ki = 1.40 nM) but weak affinities (IC50 values are approximately 1 microM) for six other neurotransmitter receptors (adenosine1, 5-HT1A, 5-HT1C, dopamine transporter, alpha2A and alpha2A) and negligible affinities (IC50 values are over 10(-5) M) for 42 other receptors, including neurotransmitters and hormones, ion channels and second messenger systems. Locomotor hyperactivity induced by methamphetamine (1 mg/kg i.p.) in mice was dose-dependently antagonized by NRA0045 (ED50 = 0.5 mg/kg i.p. and 1.9 mg/kg p.o., respectively). Methamphetamine (10 mg/kg i.p.)-induced stereotyped behavior in mice was dose-dependently antagonized by NRA0045, whereas NRA0045 did not exceed 50% inhibition even at the highest dose given (30 mg/kg i.p.). Catalepsy was dose-dependently and significantly induced by NRA0045 in rats, whereas NRA0045 did not exceed 50% induction even at the highest dose given (30 mg/kg i.p.). Thus NRA0045 blocks behaviors associated with activation of the mesolimbic/mesocortical dopaminergic neurons more selectively than behaviors associated with nigrostriatal dopaminergic neurons. In rats, tryptamine-induced clonic seizure, a 5-HT2 receptor-mediated behavior, was also dose-dependently inhibited by NRA0045 (ED50 = 1.7 mg/kg i.p.). Norepinephrine-induced lethality is regarded as being induced through the alpha-1 adrenoceptor. NRA0045 dose-dependently antagonized norepinephrine-induced lethality in rats (ED50 = 0.2 mg/kg i.p.). Thus NRA0045 may have a unique antipsychotic activity with regard to dopamine D4 and 5-HT2A receptors and alpha-1 adrenoceptor antagonistic activities, without producing the extrapyramidal side effects." @default.
- W1926317532 created "2016-06-24" @default.
- W1926317532 creator A5006471364 @default.
- W1926317532 creator A5020636893 @default.
- W1926317532 creator A5032866349 @default.
- W1926317532 creator A5039021133 @default.
- W1926317532 creator A5047573124 @default.
- W1926317532 creator A5059057970 @default.
- W1926317532 creator A5059490368 @default.
- W1926317532 creator A5060936385 @default.
- W1926317532 creator A5074404539 @default.
- W1926317532 creator A5074708131 @default.
- W1926317532 creator A5075625024 @default.
- W1926317532 creator A5089010280 @default.
- W1926317532 date "1997-07-01" @default.
- W1926317532 modified "2023-09-26" @default.
- W1926317532 title "In vitro and in vivo characterization of the dopamine D4 receptor, serotonin 5-HT2A receptor and alpha-1 adrenoceptor antagonist (R)-(+)-2-amino-4-(4-fluorophenyl)-5-[1-[4-(4-fluorophenyl)-4-oxobutyl] pyrrolidin-3-yl]thiazole (NRA0045)." @default.
- W1926317532 cites W14947124 @default.
- W1926317532 cites W1556416492 @default.
- W1926317532 cites W1766643663 @default.
- W1926317532 cites W1775749144 @default.
- W1926317532 cites W1809659791 @default.
- W1926317532 cites W1954888178 @default.
- W1926317532 cites W1964936180 @default.
- W1926317532 cites W1965505200 @default.
- W1926317532 cites W1966092598 @default.
- W1926317532 cites W1971290197 @default.
- W1926317532 cites W1977120421 @default.
- W1926317532 cites W1979258932 @default.
- W1926317532 cites W1984895766 @default.
- W1926317532 cites W1985582613 @default.
- W1926317532 cites W1987807082 @default.
- W1926317532 cites W1994065699 @default.
- W1926317532 cites W1996137477 @default.
- W1926317532 cites W2007980582 @default.
- W1926317532 cites W2013593246 @default.
- W1926317532 cites W2021784043 @default.
- W1926317532 cites W2022151784 @default.
- W1926317532 cites W2030121284 @default.
- W1926317532 cites W2030635333 @default.
- W1926317532 cites W2033428309 @default.
- W1926317532 cites W2034269648 @default.
- W1926317532 cites W2042145943 @default.
- W1926317532 cites W2046291435 @default.
- W1926317532 cites W2050563394 @default.
- W1926317532 cites W2053173214 @default.
- W1926317532 cites W2058878704 @default.
- W1926317532 cites W2059230444 @default.
- W1926317532 cites W2070950079 @default.
- W1926317532 cites W2072069319 @default.
- W1926317532 cites W2074631079 @default.
- W1926317532 cites W2075028631 @default.
- W1926317532 cites W2079552625 @default.
- W1926317532 cites W2091190659 @default.
- W1926317532 cites W2095148556 @default.
- W1926317532 cites W2106410122 @default.
- W1926317532 cites W2134812217 @default.
- W1926317532 cites W2151303352 @default.
- W1926317532 cites W2165075766 @default.
- W1926317532 cites W2243263130 @default.
- W1926317532 cites W2416785656 @default.
- W1926317532 cites W2949936188 @default.
- W1926317532 cites W2476290501 @default.
- W1926317532 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9223539" @default.
- W1926317532 hasPublicationYear "1997" @default.
- W1926317532 type Work @default.
- W1926317532 sameAs 1926317532 @default.
- W1926317532 citedByCount "11" @default.
- W1926317532 countsByYear W19263175322015 @default.
- W1926317532 countsByYear W19263175322018 @default.
- W1926317532 crossrefType "journal-article" @default.
- W1926317532 hasAuthorship W1926317532A5006471364 @default.
- W1926317532 hasAuthorship W1926317532A5020636893 @default.
- W1926317532 hasAuthorship W1926317532A5032866349 @default.
- W1926317532 hasAuthorship W1926317532A5039021133 @default.
- W1926317532 hasAuthorship W1926317532A5047573124 @default.
- W1926317532 hasAuthorship W1926317532A5059057970 @default.
- W1926317532 hasAuthorship W1926317532A5059490368 @default.
- W1926317532 hasAuthorship W1926317532A5060936385 @default.
- W1926317532 hasAuthorship W1926317532A5074404539 @default.
- W1926317532 hasAuthorship W1926317532A5074708131 @default.
- W1926317532 hasAuthorship W1926317532A5075625024 @default.
- W1926317532 hasAuthorship W1926317532A5089010280 @default.
- W1926317532 hasConcept C126322002 @default.
- W1926317532 hasConcept C134018914 @default.
- W1926317532 hasConcept C137183658 @default.
- W1926317532 hasConcept C170493617 @default.
- W1926317532 hasConcept C185592680 @default.
- W1926317532 hasConcept C44208683 @default.
- W1926317532 hasConcept C513476851 @default.
- W1926317532 hasConcept C55493867 @default.
- W1926317532 hasConcept C71924100 @default.
- W1926317532 hasConcept C86803240 @default.
- W1926317532 hasConcept C98274493 @default.
- W1926317532 hasConceptScore W1926317532C126322002 @default.
- W1926317532 hasConceptScore W1926317532C134018914 @default.
- W1926317532 hasConceptScore W1926317532C137183658 @default.
- W1926317532 hasConceptScore W1926317532C170493617 @default.